• 出版社/出版日：Mordor Intelligence / 2020年4月20日
|Single User||￥463,250 (USD4,250)||▷ お問い合わせ|
|Team User||￥517,750 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥817,500 (USD7,500)||▷ お問い合わせ|
The Ceftiofur market studied was anticipated to grow with a CAGR of 5.6% during the forecast period. The major factor attributing to the growth of the market is a rise in the death rate among swine and cattle around the world with reproductive tract infections, skin & soft tissue infections. Higher demand for ceftiofur antibiotics can be owing to their approval for treatment of bacterial respiratory disease associated with various bacterium. These bacteria include Actinobacillus pleuropneumoniae and Streptococcus suis infections among swine, and Mannheimia haemolytica and Haemophilus somnu among cattle. As per the study report published by the Centers for Disease Control and Prevention in June 2019, an estimated number of 48.8 million illnesses and 959,000 hospitalizations were recorded in the United States with Swine Flu. Thus, a rise in the outbreak of flu and increased research activities is expected to fuel the growth of the ceftiofur market.
Key Market Trends
Swine Sub-segment is Expected to Hold the Major Market Share in the Ceftiofur Market
Swine sub-segment is expected to account for the largest market revenue share during the forecast period. This dominance is owing to increased awareness about animal health and protein-rich foods for pet animals. Also, the increased revenue can be attributed to their higher consumption across the world. According to the statistics published by The National Pork Board for the year 2018, the World Per Capita Pork Consumption shares 40.1% of total meat consumption across the globe. Thus, increased demand for these antibiotics is expected to increase to maintain a healthy swine population. Furthermore, a rise in fundings by government authorities and livestock producers for research activities to develop are likely to create more opportunities that are fueling the growth of the segment.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall ceftiofur market. The dominance can be due to the presence of feral swine in large volumes across the US which carries pathogens capable of infecting domestic livestock. Thus, the rising prevalence of Classical swine fever (CSF) and Swine Influenza due to leads to higher demand for the ceftiofur. According to the National Center for Biotechnology Information report published in 2018, about 6 million feral swine roam in the US and are believed to be found in at least 35 states leading to the CSF among the people in the United States. Thus, higher incidences of drug overdose deaths in the region demand immediate and effective antidotes propelling the growth of the market in the region. Also, a highly developed healthcare system and huge R&D investments by key market players in the region fuel the market. Furthermore, funding through SHIC by the livestock producers to rapidly diagnose the disease caused by viruses such as detection of SADS-CoV is driving the growth of the market.
The ceftiofur market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are developing new products with lesser side effects and launching across the world. Some of the companies which are currently dominating the market are Hester Biosciences Limited., Hipra, Zoetis Inc., Merck & Co., Inc., (MSD Animal Health), and Ceva Sante Animale
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Bovine Respiratory Disease and Swine Bacterial Pneumonia
4.2.2 Favorable Initiatives by Government Authorities and Rising Awareness among Livestock Producers
4.3 Market Restraints
4.3.1 High Cost of Medication and Treatment Procedures
4.3.2 Higher Risk of Adverse Effects Associated with these Antibiotics
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Drug Type
5.1.1 Ceftiofur Sodium
5.1.2 Ceftiofur Hydrochloride
5.1.3 Ceftiofur Crystalline Free Acid
5.2 Animal Type
5.3.1 Respiratory Infections
5.3.2 Urinary Tract Infections
5.3.3 Bovine Interdigital Necrobacillosis
5.4.1 North America
18.104.22.168 United states
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Hester Biosciences Limited.
6.1.3 Zoetis Inc.
6.1.4 Merck & Co., Inc., (MSD Animal Health)
6.1.5 Ceva Sante Animale
6.1.6 APA United Nano Technology Co., Ltd
6.1.7 Laboratorios Over SRL.
6.1.8 BOVICURE PHARMA PRIVATE LIMITED
6.1.9 ZENLEY ANIMAL HEALTH
6.1.10 Vetoquinol S.A.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS